ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies
NCT ID: NCT01110473
Last Updated: 2017-11-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
52 participants
INTERVENTIONAL
2010-04-30
2013-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Monotherapy, once daily
ABT-348
An oral dose of ABT-348, once daily on Day 1, Day 8, and Day 15 of each 28 day cycle.
Monotherapy, twice daily
ABT-348
An oral dose of ABT-348, twice daily on Day 1, Day 8, and Day 15 of each 28 day cycle
Combination with Azacitidine
ABT-348
An oral dose of ABT-348, once daily on Day 1, Day 8, and Day 15 of each 28 day cycle.
ABT-348 and azacitidine
An oral dose of ABT-348 on Day 1, Day 8, and Day 15 of each 28 day cycle. An IV or injection of azacitidine on Days 1-7 of each 28 day cycle.
IV monotherapy, once daily
ABT-348
An intravenous dose of ABT-348, once daily on Day 1, Day 8, and Day 15 of each 28 day cycle.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ABT-348
An oral dose of ABT-348, once daily on Day 1, Day 8, and Day 15 of each 28 day cycle.
ABT-348
An oral dose of ABT-348, twice daily on Day 1, Day 8, and Day 15 of each 28 day cycle
ABT-348 and azacitidine
An oral dose of ABT-348 on Day 1, Day 8, and Day 15 of each 28 day cycle. An IV or injection of azacitidine on Days 1-7 of each 28 day cycle.
ABT-348
An intravenous dose of ABT-348, once daily on Day 1, Day 8, and Day 15 of each 28 day cycle.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Relapsed or refractory acute myelogenous leukemia (AML), untreated AML in subjects who are \> 60 years of age and do not have favorable cytogenetics (i.e., lack t(8,21) or inv(16)/t(16,16) or acute lymphoblastic leukemia (ALL) in subjects who have failed or are unsuitable for standard therapy.
* Chronic myelogenous leukemia (CML) subjects that have not responded or relapsed on imatinib and failed second line Tyrosine Kinase Inhibitor (TKI) therapy and are not a candidate for allogeneic bone marrow transplant.
* B-cell chronic lymphocytic leukemia (CLL) subjects that have not responded or relapsed on fludarabine or in the opinion of the Principal Investigator are unsuitable for fludarabine therapy and have not responded to or relapsed on alkylating therapy.
* Myelodysplasia (MDS) including chronic myelomonocytic leukemia (CMML) subjects with International Prognostic Scoring System (IPSS) risk categories of Intermediate-2 (INT-2) or High risk, or any myelodysplasia with symptomatic anemia resistant to erythropoietin, immunosuppressant, or DNA methyltransferase inhibitor therapy (e.g., azacitidine/decitabine).
1a. Histological or cytological confirmation of one of the following (Arm C):
* Relapsed or refractory AML, untreated AML in subjects who are \> 60 years of age and do not have favorable cytogenetics (i.e., lack t(8,21).
* Untreated MDS including CMML with IPSS risk categories of INT-2 or High risk or with more than 10% blasts in the bone marrow, or any myelodysplasia with symptomatic anemia resistant to erythropoietin, or immunosuppressant, or subject has no response after four cycles of DNA methyltransferase inhibitor therapy or subject has progressed on DNA methyltransferase inhibitor therapy.
2. Eastern Cooperative Oncology Group Status of 0-2
3. Hematologic function for subjects with CLL and CML demonstrated by hemoglobin \> 9 g/dL, platelets \> 100,000/µL, ANC \> 1500/mm3
4. Serum creatinine value of ≤ 1.8 times the upper limit of normal (ULN) and either an estimated creatinine clearance value as determined by the Cockcroft-Gault formula or based on a 24 hour urine collection creatinine clearance value of ≥ 50 mL/min
5. Adequate liver function as demonstrated by serum bilirubin \< 2 x ULN and AST and ALT \< 2.5 x ULN
6. QTc interval \< 500 msec
7. Left Ventricular Ejection Fraction \> 50%
8. Women of child-bearing potential and men must agree to use adequate contraception prior to the study entry, for the duration of study participation and up to 3 months following completion of therapy.
9. Capable of understanding and complying with parameters as outlined in the protocol and able to sign informed consent, approved by an Institutional Review Board (IRB) prior to the initiation of any screening or study-specific procedures.
Exclusion Criteria
2. ALL or AML subject has received acute anti-cancer therapy within 14 days prior to Study Day 1
3. CML, CLL or myelodysplasia (MDS) subjects has received acute anti-cancer therapy within 28 days or biologic therapy within 6 weeks prior to Study Day 1. Per Investigator discretion, hydroxyurea may be used anytime during the study. Tyrosine kinase inhibitors may not be administered 7 days prior to Study Day 1.
4. Subjects with poorly controlled diabetes mellitus
5. Subject has unresolved toxicities from prior anti-cancer therapy, grade 2 or higher clinically significant toxicity (excluding alopecia)
6. Subject has had major surgery within 28 days prior to Study Day 1
7. Subject currently exhibits symptomatic or persistent, uncontrolled hypertension defined as diastolic blood pressure \> 90 mmHg or systolic blood pressure \> 140 mmHg
8. Subject has proteinuria grade \> 1
9. Subject is unable to swallow or absorb oral tablets normally
10. Subject is receiving therapeutic anticoagulation therapy. Low-dose anticoagulation (e.g., low-dose heparin or warfarin) for catheter prophylaxis will be allowed
11. Subject has infection with HIV, Hepatitis B, or Hepatitis C
12. Female subjects who are pregnant or breast feeding
13. Any medical condition which in the opinion of the study investigator places the subject at an unacceptably high risk for toxicities
14. Clinically significant uncontrolled condition(s)
15. Subjects in Arm C who have advanced malignant hepatic tumors
16. Subjects in Arm C who have hypersensitivity to azacitidine or mannitol
17. Subjects have received CYP3A inhibitors or inducers within 7 days prior to the first dose of study drug.
18. Subjects enrolled in Arm D who have hypersensitivity to drugs formulated with polyethoxylated castor oil (Cremophor).
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AbbVie (prior sponsor, Abbott)
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gary Gordon, MD
Role: STUDY_DIRECTOR
AbbVie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site Reference ID/Investigator# 59324
Scottsdale, Arizona, United States
Site Reference ID/Investigator# 26523
Atlanta, Georgia, United States
Site Reference ID/Investigator# 26522
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Garcia-Manero G, Tibes R, Kadia T, Kantarjian H, Arellano M, Knight EA, Xiong H, Qin Q, Munasinghe W, Roberts-Rapp L, Ansell P, Albert DH, Oliver B, McKee MD, Ricker JL, Khoury HJ. Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies. Invest New Drugs. 2015 Aug;33(4):870-80. doi: 10.1007/s10637-015-0242-6. Epub 2015 May 2.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
M10-943
Identifier Type: -
Identifier Source: org_study_id